Zoetis Inc. (LON:0M3Q)

Market Cap	40.29B -36.4%
Revenue (ttm)	7.03B +2.3%
Net Income	1.99B +7.5%
EPS	4.47 +10.1%
Shares Out	n/a
PE Ratio	20.29
Forward PE	18.16
Dividend	1.52 (1.20%)
Ex-Dividend Date	Jan 20, 2026

Volume	9,330
Average Volume	5,374
Open	128.15
Previous Close	127.34
Day's Range	125.02 - 128.15
52-Week Range	114.00 - 176.78
Beta	0.96
RSI	55.33
Earnings Date	Feb 13, 2026

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 14,500
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0M3Q

Financial Performance

In 2025, Zoetis's revenue was $9.47 billion, an increase of 2.28% compared to the previous year's $9.26 billion. Earnings were $2.67 billion, an increase of 7.52%.

Financial numbers in USD